Biogen Financial Ratios
NASDAQ: BIIBHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Biogen ratio analysis
Biogen earned a net margin of 13.1% in FY 2025, down from 16.9% a year earlier. Gross margin was 75.7% compared with a median of 86.4% over the prior 9 years. Return on equity reached 7.1%, meaning Biogen generated 0.07 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.34 versus 0.38 the year before, and the current ratio was 2.68. At the end of FY 2025, BIIB traded at 20.2 times earnings; across the 10 fiscal years shown, its year-end P/E ranged from 9.3 to 32.5, with a median of 15.8. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Biogen financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 20.23 | 13.61 | 32.47 | 13.27 | 23.07 | 9.87 | 9.26 | 14.75 | 26.73 | 16.75 |
| Price / sales | 2.63 | 2.29 | 3.81 | 3.96 | 3.26 | 2.93 | 3.78 | 4.85 | 5.52 | 5.41 |
| Price / book | 1.43 | 1.33 | 2.53 | 3.00 | 3.28 | 3.68 | 4.08 | 5.00 | 5.37 | 5.10 |
| Gross margin | 75.7% | 76.1% | 74.2% | 77.6% | 80.8% | 86.6% | 86.4% | 86.5% | 86.7% | 87.1% |
| Operating margin | — | — | — | — | 25.9% | 33.8% | 49.0% | 43.8% | 43.6% | 45.0% |
| Net margin | 13.1% | 16.9% | 11.8% | 29.9% | 14.2% | 29.8% | 41.0% | 32.9% | 20.7% | 32.3% |
| Free cash flow margin | 20.7% | 28.1% | 12.9% | 11.2% | 30.8% | 28.3% | 45.7% | 40.3% | 30.0% | 34.7% |
| Return on equity (ROE) | 7.1% | 9.8% | 7.8% | 22.7% | 14.3% | 37.4% | 44.1% | 34.0% | 20.1% | 30.5% |
| Return on assets (ROA) | 4.4% | 5.8% | 4.3% | 12.4% | 6.5% | 16.3% | 21.6% | 17.5% | 10.7% | 16.2% |
| Debt / equity | 0.34 | 0.38 | 0.47 | 0.47 | 0.79 | 0.70 | 0.56 | 0.46 | 0.00 | 0.00 |
| Current ratio | 2.68 | 1.35 | 2.00 | 2.99 | 1.83 | 1.84 | 1.72 | 2.32 | 2.34 | 2.55 |
| Revenue growth | 2.2% | -1.6% | -3.3% | -7.4% | -18.3% | -6.5% | 6.9% | 9.6% | 7.2% | 6.4% |
| EPS growth | -21.4% | 40.3% | -61.8% | 100.7% | -58.1% | -21.1% | 45.6% | 81.0% | -29.6% | 10.4% |